Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.

Authors

Institutions

Publication Details

Journal
Immunotherapy
Published
2024-09-13
DOI
https://doi.org/10.1080/1750743x.2024.2399498
Citations
2
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment

S. Tzoumpa, Alexandre Memmi, Charlée Nardin, F. Granel‐Brocard et al.
2 citations
Immunotherapy
Cancer Immunotherapy and Biomarkers
0.57
article

Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment

S. Tzoumpa, Alexandre Memmi, Charlée Nardin, F. Granel‐Brocard, Elisa Funck‐Brentano, G. Jeudy, E. Maubec, Caroline Dutriaux, M. Saint‐Jean, Yannick Le Corre, Victor Tafani, B. Villette, Gaelle Quereux
article en
2 citations

Abstract

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.

ImmunotherapyVol. 16(16-17)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris Cité (FR), Centre Hospitalier Universitaire de Besançon (FR), Université Sorbonne Paris Nord (FR), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut de Cancérologie de l'Ouest (FR), Hôpital Saint-André (FR), Hôpital Ambroise-Paré (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Groupe Hospitalier Intercommunal Le Raincy Montfermeil (FR), Immunologie et Nouveaux Concepts en Immunothérapie, Université d'Angers (FR)
Good health and well-being
Openalex Percentile: Top 28%
Cancer Immunotherapy and Biomarkers
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.